Skip to Content

Ogivri Approval History

  • FDA approved: Yes (First approved December 1, 2017)
  • Brand name: Ogivri
  • Generic name: trastuzumab-dkst
  • Company: Mylan GmbH
  • Treatment for: Breast Cancer, Stomach Cancer

Ogivri (trastuzumab-dkst) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer and the treatment of HER2-overexpressing stomach cancer.

Development History and FDA Approval Process for Ogivri

DateArticle
Dec  1, 2017Approval FDA Approves Ogivri (trastuzumab-dkst), a Biosimilar to Herceptin
Jan 11, 2017U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide